Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China

Clinical Drug Investigation

Volumn 27, Issue 6, 2007, Pages 397-405

  Pan, Chang Yu ^a   Landen, Harald ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BODY WEIGHT; CHINA; CHINESE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE;

ACARBOSE; CHINA; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES;

EID: 34249898882     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727060-00003     Document Type: Article

References (45)

1. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7
2. Harris MI. Impaired glucose tolerance: prevalence and conversion to NIDDM. Diabetic Med 1996; 13: S9-S11
3. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46: 701-10
4. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4
5. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405
6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9
7. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-40
8. Qiao Q, Jousilahti P, Eriksson J, et al. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003; 26: 2910-4
9. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Berlin, Germany 2005 [online]. Available from URL: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf [Accessed 2006 Mar 27]
10. International Diabetes Federation. Diabetes atlas [online]. Available from URL: http://www.eatlas.idf.org [Accessed 2006 May 18]
11. International Diabetes Federation. Fact sheet: impaired glucose tolerance (IGT) [online]. Available from URL: http://www.idf.org [Accessed 2006 May 18]
12. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53
13. Wang K, Li T, Xiang H. Study on the epidemiological characteristics of diabetes mellitus and IGT in China [English abstract]. Chin J Epidemiol 1998; 19: 282-5
14. Gu D, Reynolds K, Duan X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003; 46: 1190-8
15. Pan X-R, Li G-W, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-44
16. Pan X-R, Hu Y-H, Li G-W, et al. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and Diabetes Study. Diabetes Care 1993; 16: 150-6
17. Bischoff H. The mechanism of α-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995; 18: 303-11
18. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7
19. Yang W, Lin L, Qi J, et al. The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study [English abstract]. Chin J Endocrinol Metab 2001; 17: 131-6
20. Pan C-Y, Gao Y, Chen J-W, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2003; 61: 183-90
21. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA 2003; 290: 486-94
22. Breuer H-WM. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003; 41: 421-40
23. Lam KSL, Tiu SC, Tsang MW, et al. Acarbose in NIDDM patients with poor control on conventional oral agents: a 24-week placebo-controlled study. Diabetes Care 1998; 21: 1154-8
24. Chan JCN, Chan K-WA, Ho LLT, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care 1998; 21: 1058-61
25. Hwu C-M, Ho L-T, Fuh MMT, et al. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diabetes Res Clin Pract 2003; 60: 111-8
26. Lin BJ, Wu H-P, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17: 179-85
27. Sumual AR, Pandelaki K, Rotty LAW. Acarbose/metformin combination versus metformin alone in Indonesian patients with type 2 diabetes. JAFES 2003; 21: 24-31
28. Inoue S, Zimmet P (editors). The Asia-Pacific perspective: redefining obesity and its treatment. World Health Organization Western Pacific Region/International Obesity Task Force/International Association for the Study of Obesity. Hong Kong, China, 2000 [online]. Available from URL: http://www.diabetes.com.au/pdf/obesity_report.pdf [Accessed 2006 Sep 9]
29. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients. Diabetes Care 2003; 26: 881-5
30. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83
31. Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 385-94
32. Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. Post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-4
33. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
34. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
35. Lindahl B. Primary prevention of type 2 diabetes: a matter of maintaining the new lifestyle [abstract]. 1st International Congress on Prediabetes and the Metabolic Syndrome, Berlin, Germany 2005 [online]. Available from URL: http://www.c-meondiabetes.com.au/pub/ berlin_congress_prediabetes_metabolic_syndrome_2005.php [Accessed 2006 May 31]
36. Holman RR, Blackwell L, Stratton IM, et al. Six-year results from the Early Diabetes Intervention Trial [abstract]. Diabetic Med 2003; 20 Suppl. 2: 1-33, A54
37. Hanefeld M, Chiasson J-L, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-8
38. Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus: a postmarketing surveillance study. Clin Drug Invest 2005; 25 (10): 651-9
39. Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Sys Rev 2006; issue 4. Art. No.: CD005061. DOI: 10.1002/14651858.CD005061.pub2 [online]. Available from URL: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005061/ pdf_fs.html [Accessed 2007 Jan 24]
40. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999; 57: 19-29
41. Hung Y-J, Kuo S-W, Wang C-H, et al. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Invest 2006; 26 (10): 559-65
42. Van de Laar FA, Lucassen PL, Akkermans RP, et al. α-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28 (1): 166-75
43. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Reviews 1998; 6 (2): 132-45
44. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-54
45. Holman RR, Cull CA, Turner RC, et al. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22 (6): 960-4